Single versus combination intravenous anti-pseudomonal antibiotic therapy for people with cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 12, 2016, Pages

  Elphick, Heather E ^a   Scott, Alison ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; BETA LACTAM ANTIBIOTIC; ANTIINFECTIVE AGENT; BETA LACTAM; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC THERAPY; BACTERIOLOGY; COMPARATIVE STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG POTENTIATION; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC SCREENING; HOSPITALIZATION; HUMAN; INTENTION TO TREAT ANALYSIS; LUNG FIBROSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUALITY OF LIFE ASSESSMENT; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; BACTERIAL INFECTIONS; COMBINATION DRUG THERAPY; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; PROCEDURES; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTIONS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; CEPHALOSPORINS; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, INTRAVENOUS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS;

EID: 85002735919     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002007.pub4     Document Type: Review

References (86)

1. Costantini D, Padoan R, Brienza A, Lodi G, Assael BM, Giunta A. Clinical evaluation of carbenicillin and sisomycin alone or in combination in CF patients with pulmonary exacerbations [abstract]. Proceedings of the 11th European Cystic Fibrosis Conference. 1982:227. [CFGD Register: PI122; 3132057]
2. Huang NN, Palmer J, Braverman S, Keith HH, Schidlow D. Therapeutic efficacy of ticarcillin and carbenicillin in patients with cystic fibrosis: a double blind study [abstract]. 23rd Cystic Fibrosis Club Abstracts; 1982 May 14; Washington DC. 1982:124. [CFGD Register: PI114; 3132059]
3. Master V, Martin AJ, Holmes M, Roberts G, Coulthard K. Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients [abstract]. European Respiratory Journal 1997;10(Suppl 25):162s. [CFGD Register: PI148a; 3132061]
4. Master V, Roberts GW, Coulhard KP, Baghurst PA, Martin A, Roberts ME, et al. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study. Pediatric Pulmonology 2001;31(5):367-76. [CFGD Register: PI148b; 3132062]
5. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatric Pulmonology 1988;4(4):201-4. [CFGD Register: PI58; 3132064]
6. McLaughlin FJ, Matthews WJ Jr, Strieder DJ, Sullivan B, Goldmann DA. Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;11 Suppl B:195-203. [CFGD Register: PI26a; 3132066]
7. McLaughlin FJ, Matthews WJ, Strieder DJ, Sullivan B, Taneja A, Murphy P, et al. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo. The Journal of Infectious Diseases 1983;147(3):559-66. [CFGD Register: PI26b; 3132067]
8. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. Journal of Pediatrics 1977;90(1):144-8. [CFGD Register: PI17; 3132069]
9. Pedersen SS, Pressler T, Pedersen M, Hoiby N, Friis-Moller A, Kock C. Immediate and prolonged clinical efficacy of Ceftazidime versus Ceftazidime plus Tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scandinavian Journal of Infectious Diseases 1986;18:133-7. [CFGD Registere: PI42; 3132071]
10. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a B-lactam alone versus B-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 1999;134(4):413-21. [CFGD Register: PI152; 3132073]
11. Adeboyeku D, Jones AL, Hodson ME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):25-30. [CFGD Register: PI243; 3132075]
12. Al Ansari NA, Foweraker J, Mackeown D, Bilton D. Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients [abstract]. Qatar Medical Journal 2006;15(1):34-8. [CFGD Register: PI173b; 3132077]
13. Al-Ansari N, McKeon D, Parmer J, Gunn E, Foweraker J, Bilton D. Efficacy of once daily tobramycin for acute pulmonary exacerbations of cystic fibrosis (CF) - a microbiological perspective [abstract]. Thorax 2001;56(Suppl 3):iii85. [CFGD Register: PI173a; 3132078]
14. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 2002;50(4):553-9. [CFGD Register: PI158b; 3132080]
15. Tsang L, Aminimanizani A, Beringer PM, Jelliffe R, Shapiro B. Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):284. [CFGD Register: PI158a; 3132081]
16. Balsamo V, Bragion E, Iapichino L, Natozi D, Pardo F. Clinical efficacy and "in vitro" activity of some antibiotics, ceftazidime aztreonam or carbenicillin with aminoglycosides against Pseudomonas in Cystic fibrosis patients [abstract]. 14th Annual Meeting of the European Working Group for Cystic Fibrosis. 1986:63. [CFGD Register: PI84; 3132083]
17. Beaudry PH, Marks MI, McDougall D, Desmond K, Rangel R. Is anti-Pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?. Journal of Pediatrics 1980;97(1):144-7. [CFGD Register: PI21a; 3132085]
18. Beaudry PH, Marks MI, Rangel R, McDougall D, Desmond K. Is anti-pseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis? [abstract]. 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia. 1979:1. [CFGD Register: PI21b; 3132086]
19. Beringer P, Owens H, Nguyen A, Benitez D, Boyd-King A, Rao AP. Safety, pharmacokinetics and preliminary evaluation of the antiinflammatory effect of doxycycline in CF [abstract]. Pediatric Pulmonology 2010;45 Suppl 33:370, Abstract no: 422. [CFGD Register: PI256a; 3132088]
20. Beringer PM, Owens H, Nguyen A, Benitez D, Rao A, D'Argenio DZ. Pharmacokinetics of doxycycline in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2012;56(1):70-4. [CFGD Register: PI256b; 3132089]
21. Blumer JL, Minkwitz M, Saiman L, San Gabriel P, Iaconis J, Melnick D. Meropenem (MEM) compared with ceftazidime (CAZ) in combination with tobramycin (TOB) for treatment of acute pulmonary exacerbations (APE) in patients with cystic fibrosis (CF) infected with Pseudomonas aeruginosa (PA) or Burkholderia cepacia (BC) [abstract]. Pediatric Pulmonology 2003;Suppl 25:294. [CFGD Register: PI179a; 3132091]
22. Blumer JL, Saiman L, Konstan MW, Melnick D. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128(4):2336-46. [CENTRAL: 531312; CFGD Register: PI179b; CRS: 5500100000006414; 3132092; PUBMED: 16236892]
23. Bosso JA, Black PG. A comparative trial of aztreonam and tobramycin plus azlocillin [abstract]. Excerpta medica, Asia Pacific Congress Series 1988;74:R(c)17. [CFGD Register: PI59a; 3132094]
24. Bosso JA, Black PG. Controlled trial of aztreonam vs tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Diseases Journal 1988;7(3):171-6. [CFGD Register: PI59b; 3132095]
25. Church DA, Kanga JF, Kuhn RJ, Rubio TT, Spohn WA, Stevens JC, et al. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. Pediatric Infectious Diseases Journal 1997;16(1):97-105. [CFGD Register: PI115; 3132097]
26. Conway SP, Pond M, Watson A, Etherington C, Robey HL, Goldman MH. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52(11):987-93. [CFGD Register: PI103c; 3132099]
27. Conway SP, Pond M, Watson A, Robey H, Goldman M. A safety profile of intravenous colomycin in adult care [abstract]. 20th European Cystic Fibrosis; 1995 June 18-21; Brussels, Belgium. 1995:P3. [CFGD Register: PI103a; 3132100]
28. Conway SP, Pond MN, Watson AJ, Robey H, Goldman MH. Colistin alone or in combination with a second antibiotic is effective in the treatment of respiratory exacerbations in cystic fibrosis [abstract]. Pediatric Pulmonology 1996;Suppl 13:296. [CFGD Register: PI103b; 3132101]
29. de Boeck K, Smet M, Eggermont E. Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy. Pediatric Pulmonology 1989;7(3):171-3. [CFGD Register: PI61; 3132103]
30. de Boeck K, Sauer K, Vandeputte S. Meropenem versus ceftazidime plus tobramycin for pulmonary disease in CF patients [abstract]. The Netherlands Journal of Medicine 1999;54:S39. [CFGD Register: PI150; 3132105]
31. Donati MA, Guenette G, Auerbach H. Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. Journal of Pediatrics 1987;111(1):28-33. [CFGD Register: PI143; 3132107; MEDLINE: 87253633]
32. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric Infectious Disease 1985;4(2):172-7. [CFGD Register: PI35; 3132109]
33. Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J. Lung clearance index: a tool to assess the response to intravenous treatment among children with cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2013;12 Suppl 1:S26, Abstract no: WS13.3. [CFGD Register: PI265; 3132111]
34. Hoogkamp-Korstanje JA, van der Laag J. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;12(2):175-83. [CFGD Register: PI140; 3132113]
35. Hubert D, Le Roux E, Lavrut T, Wallaert B, Scheid P, Manach D, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrobial Agents and Chemotherapy 2009;53(9):3650-6. [CFGD Register: PI180b; 3132115]
36. Hubert D, Wallaert B, Scheid P, Ramel S, Grenet D, Sermet-Gaudelus I, et al. Continuous infusion versus intermittent administration of ceftazidime in cystic fibrosis patients [abstract]. Pediatric Pulmonology 2003;Suppl 25:294. [CFGD Register: PI180a; 3132116]
37. Hyatt AC, Chipps BE, Kumor KM, Mellits ED, Lietman PS, Rosenstein BJ. A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1981;99(2):307-11. [CFGD Register: PI23; 3132118]
38. Jewett CV, Ledbetter J, Lyrene RK, Brasfield DM, Tiller RE. Comparison of cefoperazone sodium vs methicillin, ticarcillin and tobramycin in treatment of pulmonary exacerbations in patients with cystic fibrosis. Journal of Pediatrics 1985;106(4):669-72. [CFGD Register: PI36; 3132120]
39. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, et al. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrobial Agents and Chemotherapy 2011;55(7):3393-8. [CFGD Register: PI251; 3132122]
40. Kenny S, Hall V, Goldsmith C, Moore J, Rendall JC, Elborn JS. Eradication of Pseudomonas aeruginosa in adults with CF [abstract]. Journal of Cystic Fibrosis 2009;8(Suppl 2):S39, Abstract no: 158. [CFGD Register: PI229; 3132124]
41. Krause PJ, Young LS, Cherry JD, Osher AB, Spencer MJ, Bryson YJ. The treatment of exacerbations of pulmonary disease in cystic fibrosis: netilmicin compared with netilmicin and carbenicillin. Current Therapeutic Research Clinical and Experimental 1979;25:609. [CFGD Register: PI166; 3132126]
42. Kuni CC, Regelmann WE, duCret RP, Boudreau RJ, Budd JR. Aerosol scintigraphy in the assessment of therapy for cystic fibrosis. Clinical Nuclear Medicine 1992;17(2):90-3. [CFGD Register: PI236; 3132128]
43. Levy J, Baran D, Klastersky J. Comparative study of the antibacterial activity of amikacin and tobramycin during Pseudomonas pulmonary infection in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 1982;10(3):227-34. [CFGD Register: PI134; 3132130]
44. McCabe D, Rodgers HC. Evaluation of a twice daily tobramycin regimen in adult cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2013;12 Suppl 1:S71, Abstract no: 89. [CFGD Register: PI266; 3132132]
45. Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Pediatric Infectious Disease 1986;5(4):440-3. [CFGD Register: PI38b; 3132134]
46. Nelson JD. Management of acute pulmonary exacerbations in cystic fibrosis: a critical appraisal. Journal of Pediatrics 1985;106:1030-4. [CFGD Register: PI38a; 3132135]
47. Noah T, Ivins S, Abode K, Harris W, Henry M, Leigh M. Comparison of antibiotics for early pseudomonas infection in CF: interim data analysis [abstract]. Pediatric Pulmonology 2007;42 Suppl 30:332. [CFGD Register: PI205a; 3132137]
48. Noah TL, Ivins SS, Abode KA, Stewart PW, Michelson PH, Harris WT, et al. Inhaled versus systemic antibiotics and airway inflammation in children with cystic fibrosis and Pseudomonas. Pediatric Pulmonology 2010;45(3):281-90. [CFGD Register: PI205b; 3132138]
49. Padoan R, Cambisano W, Constantini D, Crossignani R, Giunta A. Pseudomonas pulmonary infections in cystic fibrosis: Ceftazidime vs ceftazidime plus sisomicin vs piperacillin plus sisomicin [abstract]. 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:Poster 4.21. [CFGD Register: PI52a; 3132140]
50. Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, et al. Ceftazidime monotherapy vs combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatric Infectious Diseases Journal 1987;6(7):648-53. [CFGD Register: PI52b; 3132141]
51. Permin H, Koch C, Hoiby N, Christensen HO, Moller AF, Moller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 1983;12(Suppl A):313-23. [CFGD Register: PI29; 3132143]
52. Prayle A, Jain K, Watson A, Smyth AR. Are morning doses of intravenous tobramycin less nephrotoxic than evening? Evidence from urinary biomarkers in the critic study [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:299, Abstract no: 261. [CENTRAL: 980338; CFGD Register: CO55; CRS: 5500125000000420; 4479405]
53. Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37(5):424-31. [CFGD Register: PI154f; 3132145]
54. Riethmueller J, Busch A, Franke P, Ziebach R, von Butler R, Stern M. Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:166. [CFGD Register: PI154a; 3132146]
55. Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al. Optimised intravenous antibiotic treatment with ceftazidime (thrice daily vs continuous) and tobramycin (thrice vs once daily) in CF patients [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P192. [CFGD Register: PI154b; 3132147]
56. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37(5):418-23. [CFGD Register: PI154e; 3132148]
57. Schroeter T, Eggert P, Riethmueller J, Stern M, Claass A. Acute-phase nephrotoxicity of tobramycin in CF patients: A prospective randomized trial of once-versus thrice-daily dosing [abstract]. Pediatric Pulmonology 2002;Suppl 24:289. [CFGD Register: PI154d; 3132149]
58. Schroeter TW, Eggert P, Riethmueller J, Stern M, Claass A. A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract]. 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P190. [CFGD Register: PI154c; 3132150]
59. Roberts GW, Nation RL, Jarvinen AO. Measurement of serum tobramycin in the presence of ticarcillin or piperacillin. Australian Journal of Hospital Pharmacy 1992;22(2):152-4. [CFGD Register: PI132b; 3132153]
60. Roberts GW, Nation RL, Jarvinen AO, Martin AJ. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients. British Journal of Clinical Pharmacology 1993;36(4):372-5. [CFGD Register: PI132a; 3132152]
61. Semykin SY, Polikarpova SV, Dubovik LG, Kashirskaya NY. Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic pseudomonas aeruginosa infection [abstract]. Journal of Cystic Fibrosis 2010;9 Suppl 1:S55, Abstract no: 214. [CFGD Register: PI246; 3132155]
62. British Thoracic Society Research Committee. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms. Thorax 1985;40(5):358-63. [CFGD Register: PI37a; 3132157]
63. Stack BHR, Geddes DM, Williams KJ, Dinwiddie R, Selkon JB, Godfrey RC. Ceftazidime compared with a combination of gentamicin and carbenicillin in cystic fibrosis patients with persistent pulmonary pseudomonas infection and an acute exacerbation of respiratory symptoms [abstract]. 9th International Cystic Fibrosis Congress; 1984 June 9-15; Brighton, England. 1984:4.16. [CFGD Register: PI37b; 3132158]
64. Turner R, Biondo LR, Slain D, Phillips U, Cardenas SC, Moffett K. A randomized pilot study of continuous versus intermittent infusion piperacillin-tazobactam for the treatment of pulmonary exacerbations in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 2013;48 Suppl 36:326, Abstract no: 332. [CENTRAL: 980337; CFGD Register: PI272; CRS: 5500125000000418; 4479407]
65. Wesley AW, Quested C, Edgar BW, Lennon DR. A double-blind comparison of ceftazidime with tobramycin and ticarcillin in the treatment of exacerbations of pseudomonas chest infection in children with cystic fibrosis [abstract]. Proceedings of the 10th International Cystic Fibrosis Congress; 1988 March 5-10; Sydney, Australia. (Excerpta Medica, Asia Pacific Congress Series, No. 74). 1988:13. [3132160]
66. Watson A, Whitehead A, Conway SP, Etherington C. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. Pediatric Pulmonology 1999;28(19):262-3. [CFGD Register: PI149b; 3132162]
67. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. European Respiratory Journal 2002;19(2):303-9. [CFGD Register: PI149c; 3132163]
68. Whitehead A, Conway SP, Etherington C, Dave J. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. The Netherlands Journal of Medicine 1999;54(Suppl):S36-7. [CFGD Register: PI149a; 3132164]
69. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe. American Journal of Respiratory and Critical Care Medicine 1995;151(4):939-41.
70. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9028):639-42.
71. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
72. Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients. Pediatric Pulmonology 1999;28(3):159-66.
73. Hoiby N. Antibiotic therapy for chronic infection of pseudomonas in the lung. Annual Review of Medicine 1993;44:1-10.
74. Katbamna B, Homnick DN, Marks JH. Contralateral suppression of distortion product otoacoustic emissions in children with cystic fibrosis: effects of tobramycin. Journal of the American Academy of Audiology 1998;9(3):172-8.
75. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatric Pulmonology 1997;24(2):137-42.
76. Kucers A, Crowe S, Grayson M, Hoy J (editors). The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. 5th Edition. Oxford: Hodder Arnold, 1997. [ISBN-10: 0750601558]
77. Levy SB. Antimicrobial resistance: bacteria on the defence. Resistance stems from misguided efforts to try to sterilise our environment. BMJ 1998;317(7159):612-3.
78. Mulherin D, Fahy J, Grant W, Keogan M, Kavanagh B, FitzGerald M. Aminoglycoside induced ototoxicity in patients with cystic fibrosis. Irish Journal of Medical Science 1991;160(6):173-5.
79. Regelmann WE, Elliott GR, Warwick WJ, Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease 1990;141(4 Pt 1):914-21.
80. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical Evidence of Bias. JAMA 1995;273(5):408-12.
81. Tan KH, Hyman-Taylor P, Mulheran M, Knox A, Smyth A. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers. Paediatric Pulmonology 2002;33(2):165.
82. Taylor RF, Hodson ME. Cystic Fibrosis: antibiotic prescribing practices in the United Kingdom and Eire. Respiratory Medicine 1993;87(7):535-9.
83. Wolter JM, Bowler SD, McCormack JG. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Australian and New Zealand Journal of Medicine 1999;29(1):15-21.
84. Elphick HE, Tan A, Ashby D, Smyth RL. Systematic reviews and lifelong diseases. BMJ 2002;325(7360):381-4.
85. Elphick HE, Tan AA. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002007.pub2]
86. Elphick HE, Jahnke N. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD002007.pub3]